TRAVERE THERAPEUTICS INC. - COMMON STOCK

17.92

22-August-25 13:45:00

15 minutes delayed

Stocks

+0.13

+0.73%

Today's range

17.71 - 18.37

ISIN

N/A

Source

NASDAQ

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 Sep 2024 14:00:00 By Nasdaq GlobeNewswire
Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference

10 Sep 2024 13:01:00 By Nasdaq GlobeNewswire
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy

05 Sep 2024 14:34:13 By Nasdaq GlobeNewswire
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024

22 Aug 2024 13:30:00 By Nasdaq GlobeNewswire
Travere Therapeutics to Present at Upcoming Investor Conferences

06 Aug 2024 13:30:00 By Nasdaq GlobeNewswire
Travere Therapeutics Reports Second Quarter 2024 Financial Results

01 Aug 2024 13:01:00 By Nasdaq GlobeNewswire
Travere Therapeutics to Report Second Quarter 2024 Financial Results

25 Jul 2024 13:30:00 By Nasdaq GlobeNewswire
Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

08 Jul 2024 13:30:00 By Nasdaq GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 Jun 2024 14:00:00 By Nasdaq GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

15 May 2024 14:00:00 By Nasdaq GlobeNewswire
Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress

09 May 2024 13:30:56 By Nasdaq GlobeNewswire
Travere Therapeutics to Present at Upcoming Investor Conferences

08 May 2024 13:30:00 By Nasdaq GlobeNewswire
Travere Therapeutics Reports First Quarter 2024 Financial Results

06 May 2024 13:01:00 By Nasdaq GlobeNewswire
Travere Therapeutics to Report First Quarter 2024 Financial Results

29 Apr 2024 13:30:00 By Nasdaq GlobeNewswire
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

24 Apr 2024 04:05:00 By Nasdaq GlobeNewswire
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International

04 Apr 2024 13:30:00 By Nasdaq GlobeNewswire
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association

03 Apr 2024 13:30:00 By Nasdaq GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13 Mar 2024 14:00:00 By Nasdaq GlobeNewswire
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)

11 Mar 2024 04:05:00 By Nasdaq GlobeNewswire
Travere Therapeutics to Present at Upcoming Investor Conferences

26 Feb 2024 13:30:00 By Nasdaq GlobeNewswire

<<
<
1
2
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.